Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 1
1961 1
1962 1
1963 1
1967 1
1971 3
1972 1
1974 4
1975 3
1976 1
1977 2
1979 3
1980 3
1981 3
1982 4
1983 2
1984 3
1985 7
1986 3
1987 7
1988 7
1989 9
1990 4
1991 5
1992 5
1993 11
1994 8
1995 6
1996 6
1997 14
1998 18
1999 8
2000 14
2001 16
2002 12
2003 12
2004 14
2005 15
2006 21
2007 22
2008 23
2009 16
2010 17
2011 12
2012 27
2013 18
2014 22
2015 14
2016 18
2017 20
2018 8
2019 17
2020 20
2021 25
2022 27
2023 26
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

553 results

Results by year

Filters applied: . Clear all
Page 1
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Tilly H, et al. Among authors: burke jm. N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. N Engl J Med. 2022. PMID: 34904799 Clinical Trial.
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N, Thiery-Vuillemin A, Gross-Goupil M, Mahave M, Haas NB, Sawrycki P, Gurney H, Chevreau C, Melichar B, Kopyltsov E, Alva A, Burke JM, Doshi G, Topart D, Oudard S, Hammers H, Kitamura H, Bedke J, Perini RF, Zhang P, Imai K, Willemann-Rogerio J, Quinn DI, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. Among authors: burke jm. N Engl J Med. 2021 Aug 19;385(8):683-694. doi: 10.1056/NEJMoa2106391. N Engl J Med. 2021. PMID: 34407342 Free article. Clinical Trial.
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, Hertzberg M, Kwan YL, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Flinn IW, et al. Among authors: burke jm. Blood. 2014 May 8;123(19):2944-52. doi: 10.1182/blood-2013-11-531327. Epub 2014 Mar 3. Blood. 2014. PMID: 24591201 Free PMC article. Clinical Trial.
First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM. Flinn IW, et al. Among authors: burke jm. J Clin Oncol. 2019 Apr 20;37(12):984-991. doi: 10.1200/JCO.18.00605. Epub 2019 Feb 27. J Clin Oncol. 2019. PMID: 30811293 Free PMC article. Clinical Trial.
Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study.
Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, Misleh J, Kingsley EC, Yimer HA, Freeman B, Rao SS, Chaudhry A, Tumula PK, Gandhi MD, Manda S, Chen DY, By K, Xu L, Liu Y, Crescenzo R, Idoine A, Zhang X, Cohen A, Huang J, Sharman JP. Shadman M, et al. Among authors: burke jm. Lancet Haematol. 2023 Jan;10(1):e35-e45. doi: 10.1016/S2352-3026(22)00320-9. Epub 2022 Nov 16. Lancet Haematol. 2023. PMID: 36400069 Clinical Trial.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Belada D, Kopeckova K, Bergua Burgues JM, Stevens D, André M, Persona EP, Pichler P, Staber PB, Trneny M, Duell J, Waldron-Lynch M, Wagner S, Mukhopadhyay A, Dirnberger-Hertweck M, Burke JM, Nowakowski GS. Belada D, et al. Among authors: burke jm. Blood. 2023 Oct 19;142(16):1348-1358. doi: 10.1182/blood.2023020637. Blood. 2023. PMID: 37369099 Free PMC article. Clinical Trial.
Nucleic acid-protein condensates in innate immune signaling.
Corbet GA, Burke JM, Parker R. Corbet GA, et al. Among authors: burke jm. EMBO J. 2023 Apr 3;42(7):e111870. doi: 10.15252/embj.2022111870. Epub 2022 Sep 30. EMBO J. 2023. PMID: 36178199 Free PMC article. Review.
Quantitative systems toxicology.
Bloomingdale P, Housand C, Apgar JF, Millard BL, Mager DE, Burke JM, Shah DK. Bloomingdale P, et al. Among authors: burke jm. Curr Opin Toxicol. 2017 Jun;4:79-87. doi: 10.1016/j.cotox.2017.07.003. Epub 2017 Aug 2. Curr Opin Toxicol. 2017. PMID: 29308440 Free PMC article.
dsRNA-induced condensation of antiviral proteins modulates PKR activity.
Corbet GA, Burke JM, Bublitz GR, Tay JW, Parker R. Corbet GA, et al. Among authors: burke jm. Proc Natl Acad Sci U S A. 2022 Aug 16;119(33):e2204235119. doi: 10.1073/pnas.2204235119. Epub 2022 Aug 8. Proc Natl Acad Sci U S A. 2022. PMID: 35939694 Free PMC article.
553 results